<DOC>
	<DOCNO>NCT01362452</DOCNO>
	<brief_summary>The goal clinical research study learn infusion white blood cell ( call T cell ) genetically change safe give patient receive UCBT . Researchers want learn genetically change T-cells effective attacking cancer cell patient advance B-cell lymphoma leukemia receive UCBT , long change T-cells stay body , add standard transplant could improve patient respond treatment . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Infusion Allogeneic Umbilical Cord Blood-Derived CD19-Specific T Cells</brief_title>
	<detailed_description>T-cell infusion : The gene transfer use study involve umbilical cord blood cell take either UCB unit ( ) cell leave UCB unit process . Researchers perform gene transfer change T-cells ' DNA ( genetic material cell ) , inject change T-cells body patient receive transplant . This process call modify donor lymphocyte infusion ( DLI ) T-cell infusion . Chemotherapy UCBT : After umbilical cord blood unit identify transplant arrived hospital , admit hospital receive chemotherapy UCBT . These procedure consider part research study . You discuss procedure study doctor sign inform consent document specific detail UCBT procedure possible risk , another time . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . The T-cell Infusions : After UCBT , study doctor decide eligible T-cell infusion . You must least 42 day past UCBT without serious evidence active graft versus host disease ( GVHD ) . GVHD occur donor cell attack cell person receive transplant . The T-cell infusion give vein , usually 15-30 minute 2 day . A small dose T cell infuse first day tolerate remain dose T cell infuse within 72 hour first infusion . During infusion , vital sign check . Study Tests : Within 30 day T-cell infusion : - Blood ( 2 tablespoon ) drawn check well donate blood cell tissue mix blood . Researchers use test find successful transplant . This standard test patient receive transplant . - Blood ( 2 tablespoon ) draw research test measure number B-cells ( non-transplanted ) T-cells . Within 7 day T-cell infusion : - You physical exam . - You check possible reaction UCBT , include GVHD graft failure . - Blood ( 4 tablespoon ) draw routine test , check immune system , check HAMA immune system reaction . Within 24 hour , 3 day , 1 week ( +/- 2 day ) , 2 week ( +/- 2 day ) , 4 week ( +/- 7 day ) , 8 week ( +/- 7 day ) , 3 month ( +/- 7 day ) , 6 month ( +/- 7 day ) , 12 month ( +/- 7 day ) T-cell infusion : - You physical exam . - You check possible reaction treatment , include GVHD graft failure . - Blood ( 4 tablespoon ) draw routine test . About 1 month ( +/- 7 day ) , 2 month ( +/- 7 day ) , 3 month ( +/- 7 day ) , 6 month ( +/- 7 day ) , 12 month ( +/- 7 day ) T-cell infusion , blood ( 2 tablespoon ) draw check certain protein level . This may check often , protein may replace , doctor think need . Once Weeks 2 4 , month 6 month T-cell infusion , blood ( 1 teaspoon ) drawn check immune system . This blood draw may do time blood draw routine test possible , avoid extra `` needle stick '' . After 2nd T-cell infusion : - Blood ( 2 tablespoon ) draw research test check level infuse T-cells measure number B-cells ( non-transplanted ) T-cells . About 30 day 3 , 6 , 12 month T-cell infusion : - You physical exam , check possible reaction treatment , include GVHD graft failure . - Blood ( 2 tablespoon ) draw research test check level infuse T-cells measure number B-cells ( non-transplanted ) T-cells . Â°During Month 3 visit , part blood sample use check HAMA immune system reaction . - Urine collect routine test . - You bone marrow aspiration biopsy perform check status disease . - If lymphoma , may positron emission tomography - compute tomography ( PET-CT ) scan and/or CT scan neck , chest , abdomen , pelvis check status disease , doctor think need . Tests and/or procedure may repeat often , study doctor think need . Length Study : You may continue take part study 12 month . You take study disease get bad , infection , intolerable side effect occur , able follow study direction , T-cells engraft ( grow body ) , able receive T-cell infusion . You talk study doctor want leave study early . If take study early , still may need return routine post-transplant follow-up visit , transplant doctor decides need . Your participation study complete plan study visit 12 month last T-cell infusion . Long-Term Follow-Up : For safety reason , U.S. Food Drug Administration ( FDA ) require patient receive infusion stem cell treat gene transfer procedure must long-term follow-up least 15 year receive gene transfer . You ask sign separate consent form long-term follow-up study name Protocol 2006-0676 . This investigational study . The gene transfer ( T-cell infusion genetically change T cell ) commercially available FDA approve use type disease . Gene transfer study consider investigational . Up 54 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Patients history CD19+ lymphoid malignancy primary refractory treatment ( achieve complete remission first course therapy ) beyond first remission include second great remission active disease . 2 . Patients first remission eligible consider high risk , define follow detected time : 1 ) Acute Lymphoblastic Leukemia ( ALL ) translocation 9 ; 22 4 ; 11 , hypodiploidy , complex karyotype , secondary leukemia develop cytotoxic drug exposure , and/or evidence minimal residual disease ; , 2 ) Acute biphenotypic leukemia ; , 3 ) Double hit nonHodgkin 's lymphoma ; , 4 ) NonHodgkin 's Lymphoma ( NHL ) second third complete remission , relapse ( include relapse post autologous hematopoietic stem cell transplant ) . Double hit lymphoma first remission advance disease ; , 5 ) Small Lymphocytic Lymphoma ( SLL ) , Chronic Lymphocytic Leukemia ( CLL ) progressive disease follow standard therapy . 3 . Age 1 75 year old . 4 . Performance score least 80 % Karnofsky PS &lt; 3 ( ECOG ) ( age &gt; /= 12 year ) , Lansky PlayPerformance Scale least 60 % great ( age &lt; 12 year ) . 5 . Two Cord Blood unit identify matched patient 4/6 , 5/6 , 6/6 HLA class I ( serological ) II ( molecular ) antigen . Each cord must contain least 1.5 x 10^7 total nucleated cells/Kg recipient body weight ( prethaw ) . One Cord Blood unit may use ( lieu two ) contains least 2.5 x 10^7 total nucleated cells/Kg recipient body weight ( prethaw ) . 6 . Have identify back cell source case engraftment failure . The source autologous , related unrelated . 7 . Cardiac Function : leave ventricular ejection fraction &gt; /= 40 % . 8 . Pulmonary function : FEV1 , FVC DLCO &gt; /= 50 % expect , correct hemoglobin . For child &lt; /= 7 year age unable perform PFT , oxygen saturation &gt; /= 92 % room air pulse oximetry . 9 . Renal function : Serum creatinine &lt; /= 1.8mg/dl &lt; /= 2 x upper limit normal creatinine clearance great equal 40 cc/min . Creatinine pediatric patient &lt; /=1.5 mg/dl &lt; /=2 time upper limit normal age ( whichever less ) . 10 . Liver function : Bilirubin &lt; /= 1.5 mg/dl &lt; /= 4 x upper limit normal ( unless Gilbert 's syndrome ) , ALT AST &lt; /= 200 IU/ml &lt; /= 5 x upper limit normal adult unless related underline disease . For pediatric patient conjugate ( direct ) bilirubin &lt; 2x upper limit normal , ALT AST &lt; 5 time upper limit normal . 11 . Negative Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization willing use effective contraceptive measure study . 12 . Patient patient 's legal representative , parent ( ) guardian able provide write informed consent . Assent minor participant 's age least seven less eighteen year . 13 . Patient patient 's legal representative , parent ( ) guardian able provide write informed consent longterm followup gene therapy study . 1 . Positive beta HCG female childbearing potential define postmenopausal 12 month previous surgical sterilization breastfeeding . 2 . Patients know allergy bovine murine product . 3 . Patients known history HIV/AIDS . 4 . Patients chronic active hepatitis cirrhosis . If positive hepatitis serology , Study Chair may deem patient eligible base result liver biopsy . 5 . Patients positive West Nile Virus RPR . 6 . If opinion PI designee , research participant significant active medical illness condition deem potentially impact negatively trial participation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>CD19-specific T cell</keyword>
	<keyword>Umbilical cord blood transplantation</keyword>
	<keyword>B-Lineage Lymphoid Malignancies</keyword>
	<keyword>B-cell leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Biphenotypic Leukemia</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>SLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>White blood cell</keyword>
	<keyword>T cell</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Thiotepa</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
</DOC>